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Mutations in the chloroquine resistance transporter (PfCRT) are
the primary determinant of chloroquine (CQ) resistance in the
malaria parasite Plasmodium falciparum. A number of distinct
PfCRT haplotypes, containing between 4 and 10 mutations, have
given rise to CQ resistance in different parts of the world. Here we
present a detailed molecular analysis of the number of mutations
(and the order of addition) required to confer CQ transport activity
upon the PfCRT as well as a kinetic characterization of diverse
forms of PfCRT. We measured the ability of more than 100 variants
of PfCRT to transport CQwhen expressed at the surface of Xenopus
laevis oocytes. Multiple mutational pathways led to saturable CQ
transport via PfCRT, but these could be separated into two main
lineages. Moreover, the attainment of full activity followed a rigid
process in which mutations had to be added in a specific order to
avoid reductions in CQ transport activity. A minimum of two muta-
tions sufficed for (low) CQ transport activity, and as few as four
conferred full activity. The finding that diverse PfCRT variants are
all limited in their capacity to transport CQ suggests that resistance
could be overcome by reoptimizing the CQ dosage.
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Chloroquine (CQ) was the mainstay of malaria treatment forseveral decades before the emergence and spread of CQ-
resistant (CQR) parasites rendered it ineffective in many malarious
regions. The loss of CQ efficacy was disastrous for world health, and
another disaster will ensue if resistance to the current first-line
treatments (the artemisinin-based therapies) continues to develop
in Southeast Asia (1). Hence, there is a dire need for a readily
deployable, cost-effective strategy that does not rely on artemisinin
derivatives. Recent clinical trials conducted in the Republic of
Guinea-Bissau have suggested that CQ resistance can be overcome
simply by reoptimizing the CQ dose regimen (2–4), highlighting the
potential continuing utility of CQ as an antimalarial. However,
different CQR strains vary in the degree of CQ resistance they
exhibit, and it is not known whether CQR malaria from other
regions is susceptible to treatment by a revised dosage of CQ.
CQ is a diprotic weak base that accumulates to very high levels
within the parasite’s acidic (pH ∼5) digestive vacuole (DV) (5–7)
via weak-base trapping (8). Here CQ is thought to exert its an-
timalarial effect by preventing the detoxification of the heme
released from digested host hemoglobin. Resistance to CQ is
attributed primarily to mutations in the Plasmodium falcipa-
rum chloroquine resistance transporter (PfCRT), an integral
membrane protein localized to the DV, and is associated with
a significant reduction in CQ accumulation within the DV (9–12).
Mutations in PfCRT can also modulate the parasite’s suscepti-
bility to other current antimalarial drugs (13, 14). We recently
established a robust system for the functional characterization of
PfCRT in Xenopus laevis oocytes (15). The oocyte system allows
interactions with PfCRT to be studied directly and in isolation,
without confounding effects such as the binding of drug to heme,
other targets, or transporters within the parasite. Using this sys-
tem, we provided a mechanistic explanation for the phenomenon
of CQ resistance by showing that mutant PfCRT from the CQR
strain Dd2 (PfCRTDd2) (Fig. 1A) mediates saturable CQ transport,
whereas the wild-type form of the protein from CQ-sensitive (CQS)
strains does not (Fig. S1 and ref. 15). CQR parasites that have
arisen independently in Columbia, Peru, Papua New Guinea, the
Philippines, and Southeast Asia (Fig. 1A) have distinct PfCRT
haplotypes. These haplotypes all contain a mutation at position
76—the replacement of the positively-charged lysine (K) with an
uncharged residue, usually threonine (T)—but are otherwise di-
verse, containing at least 4 and up to 10 mutations (13). Here, we
used the Xenopus oocyte system to determine whether these
PfCRT proteins also mediate the saturable transport of CQ and, if
so, to ascertain the number of mutations (and the order of addi-
tion) required to confer CQ transport activity upon PfCRT.
Results
Saturability of CQ Transport via a Diverse Range of PfCRT Haplotypes.
The haplotypes of PfCRT harbored by seven distinct CQR
strains (Dd2, K1, GB4, Ecu1110, Ph1, Ph2, and 7G8) (Fig. 1A) as
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well as the CQS form of the protein (PfCRTHB3) were expressed
in oocytes, with the localization of the expressed protein to the
oocyte plasma membrane confirmed by immunofluorescence
microscopy assays (Fig. 1B and Fig. S2). Semiquantitative Western
blot analyses showed that the PfCRT proteins were present at
similar levels in the oocyte membrane in each case (Figs. S3 and
S4). The ability of the oocytes to transport [3H]CQ was measured
in an acidic medium (pH = 6), in which the majority of CQ was
protonated. All the CQR forms of PfCRT mediated CQ trans-
port, albeit to different extents (Figs. 1C and 2). Kinetic analyses
revealed that the CQR PfCRT proteins can be separated into two
main groups according to their apparent Michaelis–Menten
constants (Km) and maximum velocities (Vmax) for CQ transport;
the GB4, K1, and Dd2 variants of PfCRT have a lower affinity
for CQ and higher capacity for transport than the Ecu1110, Ph1,
Ph2, and 7G8 proteins (Table 1). A similar trend was observed
for the PfCRT-mediated transport of monodesethyl-CQ (the
main metabolite of CQ) (Fig. S5A). The finding that the CQ Km
values range from 117 to 293 μM is of physiological significance
given that a clinical course of CQ is estimated to result in 200–
600 μM of the drug in the DV of CQR parasites (Table S1).
Under these conditions, the transporter would already be oper-
ating near or at maximum capacity. Hence, a relatively modest
increase in the CQ concentration could lead to lethal levels of
the drug accumulating within the DV of CQR parasites.
The Minimal Requirement for CQ Transport via PfCRT. The roles
of the different mutations in the transport of CQ via PfCRT
were examined by generating ∼60 variants of PfCRTDd2 and
PfCRTEcu110 in which one or more of the eight (PfCRTDd2) or
four (PfCRTEcu110) resistance-associated mutations was replaced
with the wild-type amino acid residue (Fig. 2). The mutant proteins
were confirmed to be located at the oocyte surface and/or were
shown to be present at similar levels in the oocyte membrane (Figs.
S4 and S6 A and B). We have reported previously that reversal of
the K76T mutation abolishes CQ transport via PfCRTDd2 (ref. 15
and PfCRT variant D3 in Fig. 2A), and here the same change ab-
rogated the CQ transport activity of PfCRTEcu1110 (PfCRT variant
E1 in Fig. 2B). Reversal of either the N75E mutation in PfCRTDd2
(D2) or the N326D mutation in either PfCRTEcu1110 (E3) or
PfCRTPh1 (P2) also substantially reduced the protein’s ability to
transport CQ (by ∼80%, 98%, and 92%, respectively) (Fig. 2).
Reversal of the other mutations affected CQ transport activity
to a lesser extent. Reinstatement of the wild-type residue at
position 220 of PfCRTDd2 (D4) reduced the PfCRT-mediated
uptake of CQ by ∼54% (Fig. 2A), and modest decreases in CQ
transport activity were observed when M74I (D1), N326S
(PfCRT783), or R371I (D6) were reversed in PfCRTDd2 (∼18%,
21%, and 14%, respectively). Reversal of A220S (E2) or I356T (E5)
in PfCRTEcu1110 or A144T in PfCRTPh1 (P1) also resulted in minor
decreases in CQ uptake. In contrast, reinstatement of the wild-
type residue at position 271 (D5) or 356 (PfCRTK1) of PfCRTDd2
resulted in a small increase in the uptake of CQ.
These observations indicated that K76T, N75E (PfCRTDd2),
and N326D (PfCRTEcu1110 and PfCRTPh1) play pivotal roles in
enabling PfCRT to mediate CQ transport. Nevertheless, in-
troduction of K76T or N75E into PfCRTHB3 (D38 and D39,
respectively) did not result in significant uptake of CQ. However,
the addition of both mutations to PfCRTHB3 produced modest
but significant CQ transport activity (D32; ∼19% of PfCRTDd2).
None of the other Dd2 mutations imparted CQ transport activity
when combined with K76T (D31, D33–D37). Likewise, the in-
troduction of K76T and N326D into PfCRTHB3 (E6) was suffi-
cient to confer a low level of CQ transport activity (∼45% of
PfCRTEcu1110), whereas neither of the other two Ecu1110
mutations imparted CQ transport activity when combined with
Fig. 1. Saturable CQ transport by CQR PfCRT variants expressed in Xenopus oocytes. (A) The haplotype and origin of seven variants of CQR PfCRT. Residues
that differ from the wild-type amino acid sequence (HB3) are shaded gray. (B) Immunolocalization of PfCRT in the Xenopus oocyte. In each case, the ex-
pression of the PfCRT variant resulted in a fluorescent band external to the pigment layer, indicating that the protein was expressed in the oocyte plasma
membrane. The band was not present in noninjected oocytes. (C) Saturability of CQ transport via CQR variants of PfCRT. The concentration-dependence of CQ
uptake was calculated by subtracting the accumulation measured in oocytes expressing PfCRTHB3 from that in oocytes expressing CQR PfCRT at each CQ
concentration. The Km and Vmax values derived from these data are presented in Table 1. Uptake is shown as mean ± SEM from at least three separate
experiments (in each experiment, measurements were made from 10 oocytes per treatment).
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K76T (D33 and E7). Hence, the minimal requirement for (low)
CQ transport activity was N75E and K76T in PfCRTDd2 and
K76T and N326D in PfCRTEcu1110. Given that all known PfCRT
haplotypes contain either N75E/D or N326D (13), these results
indicate that PfCRT acquires the ability to transport CQ via one
of two main mutational routes, both of which entail the introduction
of K76T plus the replacement of an asparagine (N75 or N326) with
an acidic residue. These two mutational routes are referred to
henceforth as “ET” (referring to 75E and 76T) and “TD” (referring
to 76T and 326D). Somewhat surprisingly, the combination of N75E
and N326D resulted in a decrease, rather than an increase, in CQ
transport activity; the addition of N75E to PfCRTEcu1110 (C9) or
S326D to PfCRTDd2 (C14) significantly reduced CQ uptake.
The Roles of Other Resistance-Associated Mutations in the Transport
of CQ via PfCRT. The finding that the introduction of 76T and 75E
(D32) or 76T and 326D (E6) into PfCRTHB3 resulted in only low
levels of CQ uptake indicated that at least one of the other CQ
resistance-associated mutations is required for full CQ transport
activity. The addition of A220S or Q271E to the D32 variant of
PfCRTDd2 (giving rise to D26 and D27, respectively) resulted in
a marked increase in CQ transport activity, whereas all other
mutations either were without effect (D25, D28, D30; P > 0.05)
or reduced CQ uptake via PfCRT (D29; P < 0.05). Introduction
of A220S and Q271E into D32 (to generate D17; N75E-K76T-
A220S-Q271E) produced CQ transport activity on par with
that measured for PfCRTDd2 (P > 0.05). Indeed, further in-
vestigation of the transport properties of these minimal mutants
of PfCRTDd2 revealed that the kinetic parameters for CQ
transport did not differ between D17 and PfCRTDd2, whereas
variants possessing only two or three of these mutations (D26,
D27, and D32) mediated CQ transport with lower affinity and/or
capacity (Table 1 and Fig. S5B). However, in several cases the
addition of one of the remaining mutations to D17 abolished
CQ transport or caused significant decreases in activity (Fig.
2A). Introduction of M74I or R371I into D17 caused significant
reductions in CQ transport, and N326S abolished uptake alto-
gether, whereas the addition of I356T to D17 (to generate D16;
Fig. 2. CQ transport activity of variants of the Dd2, Ecu1110, or Ph1 forms of PfCRT in Xenopus oocytes. One or more of the mutations present in the (A) Dd2
and (B) Ecu1110 or Ph1 forms of PfCRT were replaced with the wild-type amino acid residue, and the resulting variants were tested for the ability to transport
[3H]CQ into oocytes. Twenty chimeras of PfCRTDd2 (representing the ET lineage) and PfCRT7G8 or PfCRTEcu1110 (representing the TD lineage) were also evaluated
for CQ transport activity. Uptake is shown as the mean ± SEM from 3–15 separate experiments (in each experiment measurements were made from 10 oocytes
per treatment). The China-e and 783 haplotypes of PfCRT were identified in CQR isolates from China and Cambodia, respectively (57, 58). ns, no significant
difference (P > 0.05) in CQ accumulation between oocytes expressing a CQR PfCRT variant and the control (noninjected and PfCRTHB3-expressing) oocytes.
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N75E-K76T-A220S-Q271E-I356T) had no effect on the ability
of the protein to mediate CQ uptake. Likewise, the addition of
M74I to D16 did not alter CQ transport activity, but incorporation
of N326S or R371I into D16 reduced the PfCRT-mediated uptake
of CQ by ∼20%. Indeed, regardless of the order in which the
remaining mutations were added to D16, all pathways resulted in
a transient ∼20% reduction in CQ transport activity before the full
complement of Dd2 mutations was attained.
In the case of PfCRTEcu1110, full CQ transport activity was
attained by the introduction of I356L into E6 (E2; ∼83% of
PfCRTEcu1110), followed by the addition of the one remaining
Ecu1110 mutation (A220S) to E2, which increased CQ transport
activity by ∼17%. However, when this order was switched, such
that A220S was introduced into E6 (resulting in E5; K76T-A220S-
N326D), there was a small but significant reduction in the
protein’s ability to transport CQ (P < 0.05). The introduction
of C72S into PfCRTEcu1110 (to generate PfCRT7G8) also
resulted in a significant decrease in the PfCRT-mediated up-
take of CQ (∼65%; P < 0.01). Likewise, the addition of C72S to
PfCRTPh1 (to generate PfCRTPh2) or to PfCRTDd2 (resulting in
C16) also reduced CQ transport (P < 0.01). Hence, for both
PfCRTDd2 and PfCRTEcu1110, the pathway to the full comple-
ment of mutations followed a constrained progression in which
mutations had to be added in a particular order to avoid sig-
nificant reductions in CQ transport activity (Fig. 3 and Fig. S7).
Transport of CQ via Chimeras of the ET and TD Lineages of PfCRT. A
chimera in which the N-terminal half of PfCRTDd2 was joined
to the C-terminal half of PfCRT7G8 (C10; M74I-N75E-K76T-
A220S-S326D-I356L) retained CQ transport activity, albeit at
a level only slightly above that measured for PfCRT7G8. This
result is consistent with the findings of a previous study in which
a transgenic parasite line expressing this Dd2-7G8 hybrid of
PfCRT was shown to possess the same level of CQ resistance as
an isogenic parasite line expressing PfCRT7G8 (16). In a number
of cases, the addition of one or more of the remaining Dd2
mutations to C10 decreased the PfCRT-mediated uptake of CQ
(e.g., C11–13). In contrast, introduction of three of the four
remaining Dd2 mutations (Q271E, N326S, and R371I) into C10
resulted in CQ transport activity greater than that measured for
PfCRTDd2 (C15; 121% of PfCRTDd2; P < 0.05). It is interesting
Table 1. Apparent Km and Vmax values for CQ transport via
a range of CQR PfCRT variants
PfCRT
variant
Apparent Km
μM
Apparent Vmax
pmol per oocyte/h n
HB3 – – –
Dd2 232 ± 11 61 ± 6 15
GB4 275 ± 16 57 ± 5 7
K1 293 ± 10 79 ± 17 6
Ecu1110 191 ± 17 36 ± 4 5
7G8 117 ± 6 9 ± 1 6
Ph1 186 ± 12 22 ± 3 6
Ph2 127 ± 12 12 ± 1 7
Dd2T76I 209 ± 10 58 ± 9 3
Dd2T76D 242 ± 26 53 ± 4 3
Dd2T76S 235 ± 13 41 ± 8 3
Dd2T76N 232 ± 26 22 ± 4 3
Dd2T76W 221 ± 23 26 ± 6 3
D4 282 ± 11 30 ± 4 3
D17 247 ± 49 61 ± 11 4
D26 356 ± 38 48 ± 9 4
D27 483 ± 52 49 ± 8 4
D32 839 ± 69 40 ± 10 4
CQR PfCRT-mediated transport was calculated by subtracting the uptake
of CQ measured in oocytes expressing PfCRTHB3 from that in oocytes express-
ing CQR PfCRT. The data are shown in Fig. 1C and Fig. S5 B and C. All values
are mean ± SEM from at least three separate experiments (in each experi-
ment measurements were made from 10 oocytes per treatment).
Fig. 3. Key mutational routes to CQR PfCRT. These schematics were constructed from the data presented in Fig. 2. The effect of a given mutation on the
ability of PfCRT to transport [3H]CQ into oocytes is represented as an increase (green arrow; P < 0.05), a decrease (red arrow; P < 0.05), or no change (blue
arrow; P > 0.05). The PfCRT haplotypes of the field isolates (underlined) and mutants are listed in Fig. 2. (A) The main mutational routes to PfCRTDd2. The
introduction of both 76T and 75E (D32) results in a modest but significant level of CQ uptake and is the foundation of the routes leading to the Dd2, GB4, K1,
China-e, and 783 haplotypes. The complete summary of the mutational pathways leading to PfCRTDd2 is presented in Fig. S7. (B) Mutational routes to
PfCRTEcu1110. This pathway begins with the introduction of both K76T and N326D and leads to haplotypes such as Ecu1110, 7G8, and Ph1.
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that both C15 and PfCRTK1 differ from PfCRTDd2 only at position
356, where they contain a hydrophobic residue (L or I, re-
spectively) instead of a hydroxyl residue (T), and that both proteins
possess ∼20% more CQ transport activity than PfCRTDd2. Hence,
depending on which other mutations were already present, the
ability of PfCRT to transport CQ increased (D9), decreased
(PfCRTK1), or remained the same (D16) following the addition of
I356T (Fig. 2A).
The two chimeras constructed from the C-terminal half of
PfCRTDd2 and the N-terminal half of either PfCRTEcu1110 (C1; K76T-
A220S-Q271E-N326S-I356T-R371I) or PfCRT7G8 (C2; C72S-K76T-
A220S-Q271E-N326S-I356T-R371I) did not mediate CQ transport.
The addition of T356L to C2 restored a low level of CQ transport
activity (C5; 2.6% of PfCRTDd2), but the introduction of other res-
idues of the 7G8 haplotype (271Q, 326D, or 371R) into C2 did not.
None of the ET-TD hybrids tested here possessed CQ trans-
port activities intermediate between the two parent proteins,
suggesting that, for the most part, the mutational routes taken by
these two lineages are mutually exclusive solutions for attaining
PfCRT-mediated CQ transport.
The Role of Position 76 in the Transport of CQ via PfCRT. The only
residues other than T to be detected at position 76 in CQR
parasites are A (identified in the CQR field isolate J9) (17) and I
and N (present in laboratory-generated CQR lines) (18). The
influence of the residue at position 76 on the ability of PfCRTDd2
to transport CQ was investigated by replacing T with each of the
other 19 amino acids (Fig. 4). The introduction of proline or a pos-
itively charged residue (R, H, or K) resulted in the loss of CQ
transport activity. All the remaining mutants transported CQ,
albeit at levels significantly below that measured in oocytes
expressing PfCRTDd2 (P < 0.001). For at least five of these
PfCRT variants, the reduction in CQ transport activity was
associated with a decrease in the Vmax for CQ transport rather
than with a change in the affinity for CQ or in the level of the
protein at the oocyte surface (Fig. S5C and Table 1). These
findings indicate that the predominance of 76T among CQR
field isolates results at least partly from its ability to confer
high-capacity CQ transport.
CQ Responses of CQS Parasites Transfected with a Minimal Mutant of
PfCRTDd2 or PfCRTEcu1110. Two minimal mutants of PfCRT—D28
(N75E-K76T-N326S) and E2 (K76T-N326D-I356L)—that pos-
sessed significant (but not full) CQ transport activity in the oo-
cyte system were expressed in P. falciparum-infected erythrocytes
to assess their ability to alter the parasite’s response to CQ. The
CQS strain HB3 was transfected with the native coding sequence
(encoding the D28, E2, Dd2, or HB3 versions of PfCRT) flanked
by the PfCRT promoter (5′) and a GFP sequence (3′). The GFP-
tagged proteins localized to the DV membrane (Fig. 5A), and
Western blot analysis confirmed that significant amounts of both
the native and GFP-tagged forms of the protein were expressed
in the transfectant lines (Fig. S8). Expression of PfCRTD28 or
PfCRTE2 decreased CQ accumulation (P < 0.01) but did not
reduce it to the level measured in the HB3 + PfCRTDd2 line (Fig.
5 B and C). Moreover, the fact that PfCRTDd2 (but not PfCRTD28
or PfCRTE2) increased the CQ IC50 in HB3 parasites indicates
that the extent to which mutant PfCRT alters the parasite’s
sensitivity to CQ is dependent on its capacity for CQ transport.
Indeed, there was also a strong positive correlation between the
capacities of the K1, Dd2, GB4, Ecu1110, Ph1, and 7G8 forms of
PfCRT to transport CQ in the oocyte system and the level of CQ
resistance exhibited by the respective parasite strain (Fig. 6 and
Table S2). For each of these CQR variants of PfCRT, the in vitro
CQ resistance index of the relevant parasite strain (listed in Table
S2) was plotted either against the CQ uptake values presented in
Fig. 2 (Fig. 6A) or against the Vmax and Km values presented in
Table 1 (Fig. 6 B and C, respectively). The CQ resistance index is
the CQ IC50 in a CQR strain divided by the CQ IC50 in a CQS
strain. The resulting R2 values were 0.858 (CQ uptake), 0.889
(Vmax), and 0.891 (Km). Exclusion of 7G8 from the analyses im-
proved the correlation between the CQ resistance index and CQ
uptake or Vmax (R
2 values of 0.944 and 0.980, respectively) but
had less effect on the relationship with Km (0.909).
Discussion
The Core CQ Resistance-Conferring Mutations in PfCRT Involve the Loss
of a Positive Charge and the Gain of Negative Charges. The findings
presented here reveal that the minimum requirement for (low) CQ
transport activity in both the ET and TD lineages of CQR PfCRT is
two mutations. One of these changes is the loss of the positively
charged K at position 76 [a mutation that has been detected in all
CQR parasites characterized to date (13)]. The second is the in-
troduction of a negative charge at either position 75 (in the ET
lineage) or position 326 (in the TD lineage). When introduced to-
gether, the loss of the positive charge (K76T) and the gain of the
negative charge (N75E or N326D) are sufficient to confer a low
level of CQ transport activity. Moreover, only four of the eight
mutations carried by the Dd2 version of PfCRT (N75E, K76T,
A220S, and Q271E) are required to confer CQ transport activity
approximately equivalent to that measured for PfCRTDd2. It is
worth noting that one of these mutations (K76T) causes the loss of
a positive charge and the gain of a hydroxyl group, two (N75E and
Q271E) result in the gain of a negative charge, and the fourth
(A220S) entails the introduction of a second hydroxyl group.
Likewise, three of the four mutations harbored by the Ecu1110 and
Ph1 forms of PfCRT involve the loss of a positive charge and the
gain of a hydroxyl group (K76T), the introduction of a negative
charge (N326D), or the gain of a second hydroxyl group (A220S or
A144T in PfCRTEcu1110 and PfCRTPh1, respectively). Together,
these changes may provide a Circe effect (19) that attracts the
protonated forms of CQ toward the binding site via electrostatic
forces, thereby increasing the rate of CQ transport.
Multiple Mutational Pathways Lead to CQR PfCRT, but Many Incur
Transient Decreases in CQ Transport Activity en Route to the Full
Complement of Mutations. Although variant D17 (N75E-K76T-
A220S-Q27IE) represents the minimum number of mutations
Fig. 4. CQ transport activity of T76X mutants of PfCRTDd2 in Xenopus
oocytes. The threonine at position 76 of PfCRTDd2 was replaced by each of
the other 19 standard α-amino acids, and the resulting T76X mutants were
tested for the ability to transport [3H]CQ into oocytes. Uptake is shown as
the mean ± SEM from 3–10 separate experiments (in each experiment,
measurements were made from 10 oocytes per treatment). ns, no significant
difference (P > 0.05) in CQ accumulation between oocytes expressing a T76X
mutant and the control (noninjected and PfCRTHB3-expressing) oocytes. See
Figs. S4C, S5C, and S6C for additional data.
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required to achieve the level of CQ transport activity displayed by
PfCRTDd2, several of the routes that lead from D17 entail small
(∼20%) but significant transient reductions in CQ transport ac-
tivity before the full complement of Dd2 mutations is attained.
This observation, together with the fact that D17 and several of its
derivatives have not been identified in field isolates, raises the
question of whether the route involving D17, D16 (N75E-K76T-
A220S-Q271E-I356T), and D7 (M74I-N75E-K76T-A220S-Q271E-
I356T) is the optimal solution for the development of PfCRT-
mediated CQ resistance in the ET lineage. One possibility is that
the D17 protein underwent a 50–60% decrease in CQ transport
activity through the acquisition of either M74I or R371I, the former
of which results in the China-e haplotype of CQR PfCRT (M74I-
N75E-K76T-A220S-Q271E). Addition of R371I to PfCRTChina-e
restores full CQ transport activity and yields PfCRTGB4 (M74I-
N75E-K76T-A220S-Q271E-R371I). The introduction of one of the
remaining Dd2 mutations, N326S or I356T, into PfCRTGB4 leads to
either a small increase (PfCRTK1; M74I-N75E-K76T-A220S-
Q271E-N326S-R371I) or a decrease (PfCRT783; M74I-N75E-
K76T-A220S-Q271E-I356T-R371I) in CQ transport activity. These
two haplotypes converge on PfCRTDd2 with the addition of the
final mutation (N326S or I356T). Given that, with the exception of
D17, all these PfCRT variants have been identified within the
parasite populations of Southeast Asia and China, this path may
represent one of the mutational routes PfCRT navigated to pro-
duce its GB4, K1, and Dd2 haplotypes.
Although all the routes originating from D17 (N75E-K76T-
A220S-Q27IE) entail one or more transient decreases in the
ability of PfCRT to transport CQ, some of the intermediate
haplotypes with reduced CQ transport activities may in fact
represent favorable tradeoffs between conferring a moderate
level of CQ resistance and maintaining the normal physiological
role of the protein, which is essential but as yet unknown (16, 20,
21). Indeed, PfCRT haplotypes of the ET lineage, particularly
those containing M74I-N75E-K76T, are associated with a signif-
icant decrease in the fitness of the parasite, to the extent that
these CQR strains are out-competed by wild-type CQS parasites
when CQ is withdrawn (22, 23). Hence, it is possible that one or
more of the intermediate haplotypes of the ET lineage possesses
sufficient CQ transport activity to ensure survival of the parasite
when exposed to medium levels of CQ pressure and that the
additional mutations found in the GB4, K1, and Dd2 haplotypes
further impair the normal function of the protein and are ad-
vantageous only when CQ use is high. Furthermore, it is impor-
tant to note that mutations in PfCRT are likely to have been
accompanied at various points by changes in other genes, some of
which may have served to maintain or even increase the parasite’s
resistance to CQ when a new mutation in PfCRT decreased its
CQ transport activity. One such possible modulator is the mul-
tidrug resistance transporter 1 (PfMDR1), certain mutations in
which have been shown to increase the in vitro CQ resistance of
some (but not all) parasites harboring mutant PfCRT (24, 25).
Other proteins that have been implicated in the CQ resistance
phenotype and which also may have served to offset decreases in
the CQ transport activity of PfCRT include the multidrug resistance-
associated proteins 1 and 2 (PfMRP1 and PfMRP2) (26, 27).
Alternatively, the ET variants of PfCRT may have evolved the
ability to transport CQ via pathways that do not entail significant
Fig. 5. CQ responses of CQS parasites (strain HB3) transfected with a minimal mutant of PfCRTDd2 or PfCRTEcu1110 (D28 and E2, respectively). (A) The HB3,
Dd2, D28, and E2 versions of PfCRT were expressed episomally as GFP-tagged proteins in the CQS P. falciparum strain HB3. In each case, live-cell imaging
revealed that fluorescence was restricted to the region surrounding the hemozoin crystals, consistent with PfCRT-GFP localizing to the DV [note that PfCRT
has been shown previously to localize to the parasite’s DV (9, 18)]. (Scale bars: 2 μm.) (B) Episomal expression of PfCRTD28 or PfCRTE2 reduced CQ accumulation,
albeit to a lesser extent than PfCRTDd2. (C) The CQ transport activity of PfCRTDd2 (but not of PfCRTD28 or PfCRTE2) was sufficient to increase the CQ IC50 in HB3
parasites. Asterisks indicate a significant difference (P < 0.01) from the HB3 strain. The data are shown as mean ± SEM from at least six separate experiments
performed on different days and with cells from different donors.
Fig. 6. Correlation between the CQ transport activity of PfCRT in oocytes and the in vitro CQ resistance index. For the Dd2, K1, GB4, Ecu1110, Ph1, and 7G8
variants of PfCRT, the in vitro CQ resistance index of the relevant parasite strain (listed in Table S2) was plotted against (A) the CQ uptake values presented in
Fig. 2 or the (B) Vmax and (C) Km values presented in Table 1. The CQ resistance index is the CQ IC50 in a CQR strain divided by the CQ IC50 in a CQS strain. In
each case, there was a strong positive correlation between the level of CQ resistance exhibited by parasite strains and the CQ transport properties of the
corresponding forms of CQR PfCRT (A: R2 = 0.858; B: R2 = 0.889; C: R2 = 0.891). All values are shown as mean ± SEM.
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decreases in CQ transport activity but which require the addition
of most or all of the eight mutations to achieve full CQ transport
activity. One such route branches at either D32 (N75E-K76T) or
D26 (N75E-K76T-A220S) with the addition of R371I (resulting
in D30 and D20, respectively). In both cases, the gain of 371I did
not alter the ability of the protein to transport CQ. D30 (N75E-
K76T-R371I), in turn, can be converted to D20 with the in-
troduction of A220S. The full complement of Dd2 mutations is
then achieved by acquiring Q271E (D10), followed by I356T
(D9), then M74I (PfCRT783), and finally N326S (PfCRTDd2).
D10 also can lead to PfCRTGB4 (with the addition of M74I) and
to PfCRTK1 (with the addition of N326S to PfCRTGB4). This
mutational route offers two advantages. First, each mutation either
maintains or increases the capacity of PfCRT for CQ transport;
hence the parasite is not reliant on existing and/or simultaneous
changes in other genes (e.g., those encoding PfMDR1, PfMRP1,
and PfMRP2) to avoid periods of reduced resistance to CQ. Sec-
ond, it describes a pathway by which one or more compensatory
changes (e.g., perhaps R371I and/or M74I) could arise at an early
stage to maintain the normal physiological function of the protein
while it develops the ability to transport CQ.
It is worth noting that a modest level of CQ transport can be
achieved in the ET lineage in the absence of N75E (D45, D46,
D40, and D2). These four variants have three mutations in
common: K76T (the key CQ resistance-conferring mutation),
Q271E (which results in the gain of a negative charge), and
N326S (which introduces a hydroxyl group). This set of three
mutations conferred a very low level of CQ transport activity
when introduced into PfCRTHB3 (D45; ∼5% of PfCRTDd2). In-
deed, D45 mediated considerably less CQ transport than the D32
variant (N75E-K76T). Hence, it is unlikely that the K76T-Q271E-
N326S route represents the main mutational pathway by which
PfCRT gains the ability to confer CQ resistance.
The mutational routes to PfCRTEcu1110 are considerably fewer
and much less complex than those identified for PfCRTDd2, as
perhaps is expected, given that PfCRTEcu1110 contains half the
number of mutations present in PfCRTDd2. The finding that
C72S reduces CQ transport activity when introduced into
PfCRTEcu1110 (to generate PfCRT7G8) is intriguing. This muta-
tion also caused a decrease in CQ uptake when added to
PfCRTPh1 (to generate PfCRTPh2) and to PfCRTDd2 (C16). The
observation that C72S is carried by a number of PfCRT field
haplotypes (13), together with the finding that it decreases CQ
transport activity when introduced into three different PfCRT
proteins, suggests that this mutation arose in response to pres-
sure exerted by another antimalarial drug. Alternatively, C72S
may improve the stability of the protein and/or increase its ca-
pacity to perform its normal physiological function.
PfCRT Acquires the Ability to Transport CQ via a Rigid Process. Our
results reveal that two distinct mutational pathways—the ET and
TD lineages—lead to CQ transport via PfCRT. However, al-
though there are multiple mutational routes by which PfCRT
may attain full CQ transport activity, our findings indicate that
this process is in fact rigid and laden with pitfalls. For example,
the ability of the protein to transport CQ is reduced significantly
if the CQ resistance-conferring mutations are not added in
a specific order or if any amino acid other than T is introduced
into position 76. Furthermore, many of the 20 chimeras gener-
ated from PfCRTDd2 (representing the ET lineage) and from
PfCRT7G8 or PfCRTEcu1110 (representing the TD lineage) pos-
sess little or no CQ transport activity, indicating that several
mutations from one lineage are not compatible or interchange-
able with mutations from the other. Moreover, it is interesting
that several of the Dd2 mutations demonstrate epistasis (28). For
instance, the N326S mutation can cause a decrease (e.g., when
introduced into D17, D16, or D7) or an increase (e.g., when
introduced into PfCRT783 or PfCRTChina-e) in CQ transport
activity; its effect depends on which other Dd2 mutations are
already present. A more complex example is the role of Q271E.
This mutation is necessary for establishing high levels of CQ
transport activity, yet reversal of Q271E in PfCRTDd2 increases
the uptake of CQ. Moreover, the addition of I356T can result in
an increase, decrease, or no change in the ability of PfCRT to
transport CQ. These seemingly contradictory observations sug-
gest that repurposing the substrate-binding site and translocation
pore of PfCRT for CQ transport requires the rearrangement of
complex interactions between a number of amino acid residues.
At certain steps within a given mutational pathway, the re-
versal or addition of some mutations (e.g., M74I and R371I) has
little or no effect on CQ transport activity. This finding raises the
possibility that these mutations have arisen in response to other
selection pressures, such as the requirement for PfCRT to
maintain its normal physiological role and/or to confer cross-
resistance to other antimalarial drugs.
The Capacity of Different CQR PfCRT Variants to Transport CQ Generally
Correlates with the in Vitro CQ Responses of the Corresponding Parasite
Strains. We found that the relative abilities of the K1, Dd2, GB4,
Ecu1110, Ph1, and 7G8 haplotypes of PfCRT to transport CQ in
the oocyte system generally correlate with the level of CQ re-
sistance exhibited by the respective parasite strain (the R2 values
were between 0.858 and 0.980). This relationship was not altogether
unexpected, given that (i) we observed a marked clustering of CQ
transport activities according to the lineage of the PfCRT variant,
such that the ET variants (K1, GB4, and Dd2) exhibited a greater
capacity for CQ transport than the TD variants (Ph1, Ecu1110, and
7G8), and (ii) the levels of CQ resistance displayed by Old World
P. falciparum strains (e.g., Dd2 and GB4) generally are greater than
those measured in NewWorld strains (e.g., Ecu1110 and 7G8) (29).
This finding indicates that the capacity of PfCRT for mediating CQ
transport is a significant factor in determining the level of CQ
resistance displayed by a parasite. The observation that 7G8 is
somewhat of an outlier is consistent with previous findings in-
dicating that the 7G8 haplotype of PfMDR1 contributes to the
CQ resistance phenotype to a greater extent than the PfMDR1
variants of other strains (29). Furthermore, although our data
indicate that the CQ transport properties of PfCRT play a key
role in determining the magnitude of resistance displayed by
a CQR parasite, changes elsewhere in the genome are known to
have the ability to increase (or decrease) resistance to CQ. In-
deed, even CQR strains that carry the same version of pfcrt as
well as the same copy number and haplotype of pfmdr1 can vary
in their in vitro CQ responses (29), indicating that additional
genetic elements contribute to the CQ resistance phenotype.
These considerations aside, the finding that the field TD
haplotypes possessed significantly less CQ transport activity than
the ET field haplotypes (and that this trend is reflected in the CQ
responses of the respective strains) raises the question of why two
different lineages of CQR PfCRT with distinct CQ transport
properties have emerged and become established in the P. falci-
parum population. One possibility is that the ET variants arose
under high levels of CQ pressure and were thus driven to evolve
large capacities for CQ transport, albeit at the cost of parasite
fitness (22, 23) (presumably caused, at least in part, by a reduction
in the ability of the ET variants to fulfill the normal function of
PfCRT). In contrast, a lower level of CQ pressure, such as might
have been prevalent in areas of low malaria transmission and/or
where the use of CQ as a prophylactic was largely unregulated and
erratic (30, 31), may have resulted in the emergence of PfCRT
variants with low to moderate CQ transport activities but with
little or no associated fitness cost [noting that parasites harboring
TD variants of PfCRT do not appear to be less fit than wild-type
strains (32)]. Alternatively, or in addition, the TD haplotypes may
be the product of selection pressures from both CQ and another
antimalarial drug. For instance, in many of the regions where TD
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haplotypes are prevalent, amodiaquine was deployed before CQ
resistance emerged (33). Moreover, parasites carrying TD variants
of PfCRT typically exhibit higher levels of resistance to mono-
desethylamodiaquine (the active metabolite of amodiaquine) than
those harboring ET versions of the protein (29). Hence, differ-
ences in the prevailing drug environments, and perhaps also in the
rate of parasite transmission (34), may have led to the emergence
and expansion of the ET lineage of in some parasite populations
and of the TD lineage in others.
Clinical Relevance of the Saturability of CQ Transport via a Range of
Different CQR PfCRT Variants. Our study has revealed that PfCRT
proteins from a broad range of CQR field isolates have the
ability to transport CQ as well as its main metabolite, desethyl-
CQ. However, in all cases the saturability of transport is such
that the protein will already be operating near or at maximum
capacity during a standard course of CQ. The demonstration that
diverse CQR PfCRT proteins saturate within clinically relevant
concentrations has significant implications for the redeployment
of CQ against CQR P. falciparum. A recent randomized clinical
trial has revealed that double-dose CQ (a twice-daily dose regi-
men which totals 50 mg CQ/kg over 3 d) is as effective as the
current gold-standard antimalarial (artemether-lumefantrine) in
treating P. falciparum infections in the Republic of Guinea-Bissau
(3). The CQR PfCRT haplotypes common to this region belong
to the ET lineage (35). We have shown that these proteins have
a lower affinity and higher capacity for CQ transport than the
haplotypes of the TD lineage. Hence, it is likely that CQR
malaria from regions around the world will be treated by a reopti-
mized CQ dosage (e.g., a dose regimen that entails twice-daily ad-
ministration or a slow-release formulation that consistently achieves
levels of CQ that saturate CQR forms of PfCRT). A reexamination
of the CQ dose regimen is both overdue and relevant; CQ remains
a first-line treatment and/or prophylactic in 21 countries (36), and
a CQ-azithromycin combination is in Phase IIb/III development for
preventative treatment in pregnant women (37). Moreover, super-
CQR strains have not emerged despite almost 20 y of widespread
deployment of high-dose CQ regimens in Guinea-Bissau.
The finding that PfCRT-mediated resistance saturates and
therefore may be overcome by a modest increase in the dosage
may also influence the use of several other current and future
quinolines that exhibit, or are likely to develop, cross-resistance
with CQ. In the former case [e.g., amodiaquine and pyronaridine
(29, 38)], resistance could be overcome by a reassessment of the
optimum dosage. In the latter case [e.g., ferroquine and naph-
thoquine (39, 40)], the dose could be designed to overwhelm
the PfCRT-based resistance mechanism and hence significantly
retard the emergence of resistance. These possibilities have im-
portant ramifications, given that the quinolines currently serve as
the long-acting partner in all antimalarial combination therapies
and will continue to do so for the foreseeable future; with the single
exception of the quinolone ELQ-300 (41), no other type of long-
acting antimalarial is in the development pipeline (42). Taken
together, our findings provide novel, detailed, and unexpected
insights into the workings of a protein that is a key determinant
of drug resistance in the malaria parasite.
Materials and Methods
Expression of PfCRT in X. laevis Oocytes and Measurements of CQ and Desethyl-
CQ Transport. A codon-harmonized version of the PfCRT sequence encoding
a retention motif-free form of the protein was expressed at the plasma
membrane of X. laevis oocytes using an approach described previously (15).
In vitro transcription, oocyte preparation, and cRNA microinjection (20 ng
per oocyte) were performed as outlined elsewhere (43). [3H]CQ (0.25 μM; 20
Ci/mmol) and [3H]desethyl-CQ (0.25 μM; 20 Ci/mmol) uptake by oocytes was
measured 3–6 d postinjection as detailed previously (43). The measurements
were made over 1–2 h at 27.5 °C and in medium that, unless otherwise
specified, contained 96 mM NaCl, 2 mM KCl, 2 mM MgCl2, 1.8 mM CaCl2,
10 mM Mes, 10 mM Tris·base (pH 6.0), and 15 μM unlabeled CQ (for [3H]CQ
uptake). In all cases, at least three separate experiments were performed (on
oocytes from different frogs), and in each experiment measurements were
made from 10 oocytes per treatment.
Site-Directed Mutagenesis of PfCRT. Mutations were introduced into the
PfCRT coding sequence via site-directed mutagenesis using the primer pairs
listed in Table S3. Primers were designed according to either the Quick-
Change site-directed mutagenesis protocol or the partial overlap method of
Zheng et al. (44). The introduction of multiple mutations into the PfCRT
coding sequence within a single reaction was achieved by using the sense
and anti-sense primers of the mutation closest to the 5′ end together with
the sense primer of each of the remaining mutation sites. All of the resulting
coding sequences were verified by sequencing.
Oocyte Membrane Preparation and Western Blot Analysis. Membranes were
isolated from PfCRT-expressing oocytes as described elsewhere (45) with the
following minor modifications. Twenty oocytes were homogenized in 1 mL
of 20 mM Tris·HCl (pH 8) supplemented with the Complete-mini EDTA–free
protease inhibitor cocktail (Roche). The homogenate was centrifuged at
100 × g (10 min; 4 °C), and the supernatant was collected and mixed by
inversion. A 37-μL aliquot was diluted to 400 μL with 20 mM Tris·HCl (pH 8.0)
and centrifuged at 21,000 × g (20 min; 4 °C). The pellet was washed with
1 mL of a buffer containing 20 mM Tris·HCl (pH 8), 1 M NaCl, and the pro-
tease inhibitor cocktail, and was centrifuged at 21,000 × g (10 min; 4 °C). The
pellet was solubilized in 25 μL of a solution comprising 1% Triton X-100, 20
mM Tris·HCl (pH 8), 10 mM NaCl, 150 mM DTT, 10% (vol/vol) b-mercaptoe-
thanol, and 25% (vol/vol ) NuPage sample loading buffer (Life Technologies).
The samples were separated on a 4–14% bis-Tris SDS-polyacrylamide gel (Life
Technologies) and transferred to a nitrocellulose membrane. The membrane
was probed with rabbit anti-PfCRT antibody (1:4,000; Genscript) followed by
HRP-conjugated goat anti-rabbit antibody (1:8,000; Life Technologies). Anti-
PfCRT is an affinity-purified polyclonal antibody raised against the N-terminal
peptide MKFASKKNNQKNSS. This sequence is present in all the PfCRT variants
included for study. The PfCRT band for each variant was detected by chem-
iluminescence (Pierce), quantified using the Image J software (46), and expressed
as a percentage of the intensity measured for the PfCRTDd2 band. Total protein
staining was used to evaluate sample loading and efficiency of transfer (47, 48).
Briefly, membranes were rinsed with milliQ water, immersed in Ponceau
S staining solution for 5 min, and rinsed with milliQ water until the back-
ground was white. Samples found to differ from the average in total protein
content were excluded from the analysis. In all cases, at least three separate
experiments were performed (on oocytes from different frogs), and in each
experiment measurements were averaged from two independent replicates.
Immunofluorescence Analysis.Oocytes expressing PfCRTwere fixed and labeled
with antibodies (20 ng per oocyte) 3 d postinjection using a protocol described
elsewhere (43). Rabbit anti-PfCRT and Alexa Fluor 488 goat anti-rabbit anti-
body were used at concentrations of 1:100 and 1:500, respectively. Oocytes
were embedded in an acrylic resin as described previously (49), and slices were
viewed using a Leica Microsystems inverted confocal laser microscope.
Parasite Protein Preparation. Blood cultures of P. falciparumwere maintained
as described previously (50) and synchronized by sorbitol treatment (51). A
10-mL aliquot (15% parasitemia; 2–3% hematocrit) was centrifuged (3,000 × g,
5 min), and the pellet was resuspended in 1 mL of PBS supplemented with
Complete-mini EDTA–free protease inhibitor cocktail. Saponin was added
(100 μL of a 1% solution) to lyse the red blood cells, and the sample was
centrifuged (15,800 × g, 5 min). The pellet was washed twice in PBS sup-
plemented with the protease inhibitor cocktail and then was triturated
15 times through a 25-G syringe. A 15-μL aliquot was combined with 147.5 μL of
PBS supplemented with protease inhibitor cocktail, 25 μL of β-mercaptoethanol
[10% (vol/vol) final concentration], and 62.5 μL NuPage sample loading buffer
[25% (vol/vol) final concentration]. Western blot analysis was performed as
described for the preparations of oocyte membrane protein.
Transfection of Parasites and Live-Cell Imaging. Native coding sequences of
pfcrt (encoding the D28, E2, Dd2, or HB3 versions of PfCRT), together with
a GFP-coding sequence, were inserted into the pARL1a+ transfection vector
(52). The resulting transfection vectors contained the PfCRT coding sequence
flanked by the PfCRT promoter (5′) and a GFP sequence (3′) and contained the
hDHFR selectable marker. Transfection of plasmid (100 μg) into the CQS
P. falciparum strain HB3 was performed as described previously (53), and the
transfectants were selected with WR99210 (5 nM). Transfectants were detected
in blood smears 28–42 d following transfection, and the parasites were cultured
in the absence of WR99210 for 2 d before commencement of the proliferation
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assays. Live-cell imaging was carried out on parasites of each transfectant line
at the trophozoite stage (26–28 h postinvasion) of the intraerythrocytic life
cycle according to a method outlined previously (54). Fluorescence was re-
stricted to the DV in more than 95% of the transfectant parasites that
were examined.
Measurements of Parasite Proliferation and CQ Accumulation. The accumula-
tion of [3H]CQ in mature trophozoite-infected erythrocytes was measured 36 h
postinvasion using a protocol described in full elsewhere (55). Parasite growth
was measured in 96-well plates using the [3H]hypoxanthine incorporation
method (56). The IC50 values were determined by nonlinear regression using the
equation y = a/[1 + (x/IC50)
c], where y is the percent parasite proliferation, a is the
maximal change in the percent parasite proliferation, x is the concentration of
CQ, and c is a fitted constant.
Statistics. Statistical comparisons were made using the Student t test for
paired or unpaired samples or ANOVA in conjunction with Tukey’s multiple
comparisons test.
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